| STOCK | DRUG | Indication | Phase | Status | Topline | Regulatory |
|---|---|---|---|---|---|---|
BDTX Black Diamond Therapeutics Inc. 💲 4.01 (-10.69%) | silevertinib | non-classical EGFRm NSCLC | Phase 2 | active | Q4 2025 | - |
INTS INTENSITY THERAPEUTICS INC. 💲 0.438 (-8.387%) | INT230-6 | early-stage, operable triple-negative breast cancer | Phase 2 | paused | - | - |
| INT230-6 | soft tissue sarcoma | Phase 3 | paused | - | - | |
| INT230-6 | advanced solid tumours | Phase 1/2 | completed | 2025-10-29 | - | |
IXHL Incannex Healthcare Inc. 💲 0.3524 (-1.316%) | IHL-42X | obstructive sleep apnea | Phase 2 | completed | - | - |
| PSX-001 | Generalized Anxiety Disorder | Phase 2 | completed | - | - | |
UNCY Unicycive Therapeutics Inc. 💲 5.67 (6.379%) | oxylanthanum carbonate (OLC) | hyperphosphatemia | Phase 3 | completed | - | NDA resubmission |